<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230889</url>
  </required_header>
  <id_info>
    <org_study_id>BL34</org_study_id>
    <nct_id>NCT04230889</nct_id>
  </id_info>
  <brief_title>Evaluation of Glucose Control in Patients With Diabetes</brief_title>
  <official_title>A Pilot Study to Evaluate Glucose Control in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, multicenter, open-labeled, parallel, three group pilot study to evaluate the
      impact of a diabetes-specific nutritional shake on glucose control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">February 15, 2018</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Glucose Response</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Change versus baseline phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Change in daily total glucose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nutrition Behaviors Self-Reported Outcome Questionnaire</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>15 Likert scale questions related to diet selection, oral nutritional supplement use, cravings and hunger control</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Questionnaire</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Adapted from National Health Interview Survey; Subject completed; 3 questions related to description of typical physical activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Habitual Snack Timing Questionnaire</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Subject completed; 3 questions related to frequency, timing and reason for snacking</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily Tracking Log</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Subject reported log of sleeping, exercise and eating information</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Measured in kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Height</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Measured in cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Measured in inches</description>
  </other_outcome>
  <other_outcome>
    <measure>Medications</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Subject reported medication usage including dose, unit, frequency and reason for use</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>Usual Diet Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Nutritional Shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Nutritional Shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Diet Group</intervention_name>
    <description>three main meals and two snacks</description>
    <arm_group_label>Usual Diet Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group 1 Nutritional Shake</intervention_name>
    <description>2 servings per day</description>
    <arm_group_label>Group 1 Nutritional Shake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group 2 Nutritional Shake</intervention_name>
    <description>2 servings per day</description>
    <arm_group_label>Group 2 Nutritional Shake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes as evidenced by the use of metformin, thiazolidinones, or
             sulfonylureas, alone or in combination, with constant dose for a least 2 months prior
             to Screening and is able to maintain medication dose throughout the duration of the
             study

          -  A1C ≥ 7.0% and ≤ 10.0%

          -  Follows a consistent eating pattern of 3 main meals with snacks

          -  BMI ≥ 25.0 and ≤ 40.0 kg/m2

          -  Stable body weight for the past 2 months prior to Screening Visit

          -  If on thyroid medication or hormone replacement therapy, dose been has been constant
             for at least 2 months prior to Screening Visit

          -  If taking vitamin C supplement &gt;60 mg/d, is willing to discontinue throughout the
             duration of the study

          -  Willing to take non-aspirin pain relievers through the duration of the study

          -  Voluntarily signed and dated an informed consent form (ICF), approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), and provided
             Health Insurance Portability and Accountability Act (HIPAA) (or other applicable
             privacy regulation) authorization prior to any participation in the study.

        Exclusion Criteria:

          -  Not taking oral anti-hyperglycemic medications (e.g., controlled by diet); is taking
             other oral anti-hyperglycemic medications other than metformin, thiazolidinones, or
             sulfonylureas; or on injectable medications (e.g., exenatide, insulin) for glucose
             control

          -  History of diabetic ketoacidosis

          -  History of metabolic/endocrine (other than diabetes), hepatic, or significant renal
             disease

          -  Follows a non-typical eating pattern, such as very low carbohydrate diet, strict
             vegetarianism

          -  Currently using diabetes-specific nutritional product(s), defined as more than one
             eating occasions per week

          -  Non-typical or erratic sleep-wake pattern, such as nightshift worker, chronic insomnia

          -  Pregnant as confirmed via urine pregnancy test, attempting to conceive or not willing
             and able to practice birth control during the study duration (only applicable to
             female subjects)

          -  Skin lesions, hyperhidrosis, eczema, psoriasis, scarring, tattoos, redness, infection
             or edema at the application sites that in the opinion of the study investigator or
             study physician could interfere with device placement or the accuracy of interstitial
             glucose measurements

          -  X-ray, MRI or CT appointment scheduled during the period of study participation, and
             the appointment cannot be rescheduled for a time before study participation starts or
             after study participation ends

          -  Current infection (requiring medication or which might be expected to require
             hospitalization); has had inpatient surgery, or corticosteroid treatment (excluding
             topical creams) in the last 3 months or antibiotics in the last 3 weeks prior to
             Screening Visit

          -  Active malignancy, excluding carcinoma in-situ of the cervix, cutaneous malignancies
             (basal cell carcinoma, squamous cell carcinoma, except melanoma)

          -  Chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis A, B
             or C, or HIV

          -  History of bariatric surgery including gastric balloon; history of gastrointestinal
             disease (e.g., crohns, colitis, celiac) or intestinal surgery that can interfere with
             consumption/digestion/absorption of study product

          -  Habitually engages in strenuous exercise (e.g., high intensity aerobic exercise;
             including heavy physical labor), duration of 1 hour or longer, 3 or more times per
             week

          -  Known to be allergic or intolerant to any ingredient found in the study products

          -  Currently taking any medications, herbals, or dietary supplements, other than allowed
             medications, during the past 4 weeks that could profoundly affect (in the opinion of
             the PI or study physician) blood glucose or appetite

          -  Eating disorder, severe dementia or delirium, history of significant neurological or
             psychiatric disorder, alcoholism, substance abuse or other conditions that may
             interfere with study product consumption or compliance with study protocol procedures

          -  Participant in a concomitant AN trial or trial of a nonregistered drug (or is within
             the 30 day follow-up period for such a trial) or that otherwise conflicts with this
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikkie Mustad, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MB Clinical Research</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Clinical Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Daibetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Partners Institute, International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

